CVSCVS Health

Customers the company names as a large share of revenue or receivables (it must name any worth 10% of revenue).

“In 2025, 2024 and 2023, revenues from the federal government accounted for 25%, 24% and 19%, respectively, of the Company’s consolidated total revenues, primarily related to contracts with CMS for coverage of Medicare-eligible individuals within the Health Care Benefits segment.”

Read it in the 10-K ↗

Parts or manufacturing that depend on one or a few suppliers.

“We acquire a substantial amount of our mail order and specialty pharmacies’ prescription drug supply from a limited number of suppliers.”

Read it in the 10-K ↗

“In some cases, we depend upon a single source of supply.”

Read it in the 10-K ↗

“Any such supply shortages or loss of any such single source of supply could adversely affect our operating results and cash flows.”

Read it in the 10-K ↗

Pending cases, settlements and what the company has set aside for them.

New “The increase in operating expenses was primarily due to approximately $1.2 billion of legacy litigation charges related to two court decisions associated with the Company’s past business practices, a $320 million opioid litigation charge related to a change in the Company’s accrual for ongoing opioid litigation matters and $288 million of pre-tax losses on Accountable Care assets, all recorded in 2025, as well as increased investments in colleagues and capabilities in 2025.”

Read it in the 10-K ↗

New “The decrease in operating income was primarily due to a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit and the $1.2 billion of legacy litigation charges described above, both recorded during the year ended December 31, 2025.”

Read it in the 10-K ↗

New “In June 2025, a court found certain subsidiaries of CVS Health Corporation liable for damages in connection with a complaint filed in February 2014, in which the government declined to intervene, related to PBM direct and indirect remuneration reporting practices for two clients from 2010 through 2016, which the Company has since modified.”

Read it in the 10-K ↗

New “The increase was primarily due to a $291 million litigation charge, $288 million in pre-tax losses on Accountable Care assets and an $83 million Health Care Delivery clinic closure charge, all recorded during 2025.”

Read it in the 10-K ↗

“Other than the controlled substances litigation accruals described below and as otherwise noted, none of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s consolidated balance sheets.”

Read it in the 10-K ↗

Promises to pay someone else's debts or losses if they cannot.

“With any of these guarantees, the Company is financially at risk if the conditions of the arrangements are not met, although the maximum amount at risk typically is limited to a percentage of the fees otherwise payable to the Company by the customer involved.”

Read it in the 10-K ↗

“The Company can limit its exposure to these guarantees by suspending the payment of claims for ASC customers that have not adequately funded the amount paid by the bank.”

Read it in the 10-K ↗

“Minimum contractual obligations underlying the guaranteed benefits in these Separate Accounts were approximately $807 million and $857 million at December 31, 2025 and 2024, respectively.”

Read it in the 10-K ↗

“As of December 31, 2025, the Company guaranteed 60 such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the consolidated balance sheets), with the maximum remaining lease term extending through 2036.”

Read it in the 10-K ↗

Conditions in loan agreements that, if broken, can make debt due early.

“As of December 31, 2025, the Company was in compliance with all of its debt covenants.”

Read it in the 10-K ↗

Contracts the company must pay for later: purchase obligations, take-or-pay deals.

No specific sentence about this in the 10-K.